Valsartan in chronic heart failure.

about

Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases.Thermal behavior and phase identification of Valsartan by standard and temperature-modulated differential scanning calorimetry.

P2860

Q37661443-8B85A391-F049-4FBD-BFB4-BAB01B618ED9 Q43572080-2DE5AEEC-F58C-4875-BF74-83A06B3C9F9B

P2860

Valsartan in chronic heart failure.

Item

http://www.wikidata.org/entity/Q36027661

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

Valsartan in chronic heart failure.

@ast

Valsartan in chronic heart failure.

@en

type

Item

label

Valsartan in chronic heart failure.

@ast

Valsartan in chronic heart failure.

@en

prefLabel

Valsartan in chronic heart failure.

@ast

Valsartan in chronic heart failure.

@en

P1476

Valsartan in chronic heart failure.

@en

P2093

Toni L Ripley

http://www.w3.org/2001/XMLSchema#string

P2860

Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

Effects of the replacement of the angiotensin converting enzyme inhibitor enalapril by the angiotensin II receptor blocker telmisartan in patients with congestive heart failure. The replacement of angiotensin converting enzyme inhibition (REPLACE) i

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.

Can angiotensin II type 2 receptors have deleterious effects in cardiovascular disease? Implications for therapeutic blockade of the renin-angiotensin system.

P304

460-469

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1345/APH.1E327

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15687480

http://www.w3.org/2001/XMLSchema#string

Valsartan in chronic heart failure.

about

P2860

P2860

Valsartan in chronic heart failure.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698